Beijing Double-Crane Pharmaceutical To Set Up Large-Scale Production Base In Wuhan
This article was originally published in PharmAsia News
Executive Summary
Beijing Double-Crane Pharmaceutical recently revealed that it will set up a large-scale pharmaceutical base with an investment of RMB 270 million in Wuhan city, Hubei province. The facility is to adopt world-standard cutting-edge technology, and upon completion will help elevate Beijing Double-Crane to the number one position in the local industry. The initial planning has been done and construction will be commencing soon. The Wuhan government is placing great importance on the project and has been providing support to the firm. (Click here for more - Chinese Language)
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.